Pioglitazone and Abiraterone Interaction

Understanding the Pioglitazone and Abiraterone Interaction

FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Pioglitazone belongs to the Thiazolidinedione class and Abiraterone belongs to the CYP17 Inhibitor class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Abiraterone blocks a protein in the liver that normally breaks down pioglitazone. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Pioglitazone has 10 total documented interactions on file in this dataset, and Abiraterone has 7. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor may need to monitor you more closely for side effects or adjust your dose of pioglitazone. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Pioglitazone or Abiraterone based on a web page, speak with your prescriber or pharmacist before making any change.